JTR-009 was advanced for further analysis of the mechanism of the APP 5′UTR as a regulatory domain for APP gene expression at the level of message translation and as a candidate for future analog-based drug development as an anti-APP and anti-Aβ blocker for potential DS and AD therapy. Here, APP is linked to Alzheimer disease.